Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Visine Red Eye Hydrating Comfort is an over-the-counter (OTC) ophthalmic solution developed and marketed by Kenvue (formerly a division of Johnson & Johnson). It is a dual-action formulation designed to provide both redness relief and ocular lubrication. The product contains two active ingredients: tetrahydrozoline hydrochloride (0.05%), a small molecule alpha-adrenergic receptor agonist that acts as a vasoconstrictor to reduce conjunctival congestion, and polyethylene glycol 400 (1.0%), which serves as a lubricant and humectant. It is indicated for the temporary relief of redness due to minor eye irritations and for the relief of burning and discomfort caused by eye dryness or exposure to wind and sun. The formulation is known for its fast-acting properties, typically providing relief within 30 seconds of administration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Visine Red Eye Hydrating Comfort.